Published in Clin Diagn Lab Immunol on September 01, 2002
Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests. Clin Vaccine Immunol (2012) 0.85
Aptamer based, non-PCR, non-serological detection of Chagas disease biomarkers in Trypanosoma cruzi infected mice. PLoS Negl Trop Dis (2014) 0.81
Revisiting the Posttherapeutic Cure Criterion in Chagas Disease: Time for New Methods, More Questions, Doubts, and Polemics or Time to Change Old Concepts? Biomed Res Int (2015) 0.78
A flow cytometry-based workflow for detection and quantification of anti-plasmodial antibodies in vaccinated and naturally exposed individuals. Malar J (2012) 0.77
Performance of TcI/TcVI/TcII Chagas-Flow ATE-IgG2a for universal and genotype-specific serodiagnosis of Trypanosoma cruzi infection. PLoS Negl Trop Dis (2017) 0.75
Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps. Adv Parasitol (2016) 0.75
Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet (1996) 3.38
Protective effects of specific antibodies in Trypanosoma cruzi infections. J Immunol (1976) 2.20
Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies. J Immunol (1982) 2.10
[MORPHOLOGICAL VARIATIONS OBSERVED IN DIFFERENT STRAINS OF TRYPANOSOMA CRUZI]. Rev Inst Med Trop Sao Paulo (1964) 2.06
Control of Chagas disease. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser (1991) 1.46
Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg (1993) 1.38
Hemocultures for the parasitological diagnosis of human chronic Chagas' disease. Rev Soc Bras Med Trop (1990) 1.33
Pathogenesis of Chagas' disease. Res Immunol (1991) 1.14
Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease. Clin Diagn Lab Immunol (1995) 1.13
[Hemoculture: sensitive technique in the detection of Trypanosoma cruzi in chagasic patients in the chronic phase of Chagas disease]. Rev Soc Bras Med Trop (1994) 1.07
Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease. Clin Diagn Lab Immunol (2001) 1.02
[Yield of xenodiagnosis in human chronic Chagas' infection using nymphs of different species of triatomid bugs]. Bol Chil Parasitol (1972) 0.95
Intraspecific variation in Trypanosoma cruzi: effect of temperature on the intracellular differentiation in tissue culture. J Parasitol (1977) 0.92
[Correlation among the positivity of the artificial xenodiagnosis and the amount of blood and triatomines used in the exam, in chronic chagasic patients]. Rev Soc Bras Med Trop (2002) 0.81
[Current prospects of specific treatment of Chagas' disease]. Bol Chil Parasitol (1998) 0.79
Complement fixation test with a triple antigen for syphilis, tuberculosis, leprosy or Chagas' disease in blood banks. Am J Trop Med Hyg (1954) 0.79
Chagas disease. Lancet (2010) 10.25
Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med (2006) 6.00
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31
Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA (2007) 5.22
American trypanosomiasis (Chagas disease). Infect Dis Clin North Am (2012) 2.04
Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation (2007) 1.99
Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J (2008) 1.99
The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz (2009) 1.54
Should tissue Doppler echocardiography be used to improve prediction of mortality risk in patients with Chagas cardiomyopathy? Int J Cardiol (2011) 1.38
Cardiac involvement with parasitic infections. Clin Microbiol Rev (2010) 1.32
Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int J Antimicrob Agents (2003) 1.27
Another disappointing result with implantable cardioverter-defibrillator therapy in patients with Chagas disease. Europace (2013) 1.08
[Guidelines for the evaluation and treatment of patients with cardiac arrhythmias]. Arq Bras Cardiol (2003) 1.06
Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem Inst Oswaldo Cruz (2009) 1.05
Deficient regulatory T cell activity and low frequency of IL-17-producing T cells correlate with the extent of cardiomyopathy in human Chagas' disease. PLoS Negl Trop Dis (2012) 1.03
Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. J Infect Dis (2011) 1.01
Combined use of enzyme-linked immunosorbent assay and flow cytometry to detect antibodies to Trypanosoma cruzi in domestic canines in Texas. Clin Diagn Lab Immunol (2004) 0.98
Infection by Trypanosoma cruzi metacyclic forms deficient in gp82 but expressing a related surface molecule, gp30. Infect Immun (2003) 0.98
Posaconazole versus benznidazole for chronic Chagas' disease. N Engl J Med (2014) 0.98
Cell therapy in Chagas cardiomyopathy (Chagas arm of the multicenter randomized trial of cell therapy in cardiopathies study): a multicenter randomized trial. Circulation (2012) 0.98
Trypanosoma cruzi surface molecule gp90 downregulates invasion of gastric mucosal epithelium in orally infected mice. Microbes Infect (2005) 0.98
Letter by Rassi and Rassi regarding article, "Ten-year incidence of Chagas cardiomyopathy among asymptomatic, Trypanosoma cruzi-seropositive former blood donors". Circulation (2013) 0.97
Neurological disease in HIV-infected patients in the era of highly active antiretroviral treatment: a Brazilian experience. Rev Soc Bras Med Trop (2006) 0.96
[A retrospective search for maternal transmission of Chagas infection from patients in the chronic phase]. Rev Soc Bras Med Trop (2005) 0.94
Combined methods for the study of water contact behavior in a rural schistosomiasis-endemic area in Brazil. Acta Trop (2005) 0.94
Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection. Parasitol Res (2006) 0.93
Update on Chagas heart disease on the first centenary of its discovery. Rev Esp Cardiol (2009) 0.92
Involvement of Ssp-4-related carbohydrate epitopes in mammalian cell invasion by Trypanosoma cruzi amastigotes. Microbes Infect (2006) 0.91
Non-conventional flow cytometry approaches to detect anti-Trypanosoma cruzi immunoglobulin G in the clinical laboratory. J Immunol Methods (2006) 0.89
Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease. Am J Cardiol (2012) 0.87
[Anti-live Leishmania (Viannia) braziliensis promastigote antibodies, detected by flow cytometry, to identify active infection in american cutaneous leishmaniasis]. Rev Soc Bras Med Trop (2003) 0.86
Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. Am J Trop Med Hyg (2007) 0.84
[Congenital transmission of Trypanosoma cruzi in Brazil: estimation of prevalence based on preliminary data of national serological surveys in children under 5 years old and other sources]. Rev Soc Bras Med Trop (2005) 0.82
Applicability of an optimized non-conventional flow cytometry method to detect anti-Trypanosoma cruzi immunoglobulin G for the serological diagnosis and cure assessment following chemotherapeutic treatment of Chagas disease. J Immunol Methods (2011) 0.82
[Correlation among the positivity of the artificial xenodiagnosis and the amount of blood and triatomines used in the exam, in chronic chagasic patients]. Rev Soc Bras Med Trop (2002) 0.81
[Treatment of chronic Chagas' disease with an association of nifurtimox and corticoid]. Rev Soc Bras Med Trop (2003) 0.79
[Optimization of the medical treatment in coronary artery disease: a task for the subspecialist?]. Arq Bras Cardiol (2004) 0.77
Implantable cardioverter-defibrillators in patients with Chagas heart disease: misperceptions, many questions and the urgent need for a randomized clinical trial. J Cardiovasc Electrophysiol (2007) 0.77
Further evidence that the expression of CD38 and HLA-DR(+) in CD8(+) lymphocytes does not correlate to disease progression in HIV-1 vertically infected children. J Int Assoc Physicians AIDS Care (Chic) (2011) 0.77
A Latin American man with palpitations, dizziness, episodes of nonsustained ventricular tachycardia, and an apical aneurysm. PLoS Negl Trop Dis (2011) 0.76
Rural electrification in Brazil and implications for schistosomiasis transmission: a preliminary study in a rural community in Minas Gerais State, Brazil. Trop Med Int Health (2012) 0.76
Letter by Rassi et al regarding article, "Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial". Circ Heart Fail (2010) 0.75
Preventing type 2 diabetes mellitus with angiotensin blockade: is it clinically relevant? J Am Coll Cardiol (2006) 0.75
Prognostic utility of coronary computed tomography angiography: are we looking at the correct outcomes and making appropriate comparisons? JACC Cardiovasc Imaging (2009) 0.75
[Evaluation of blood tests, complement-mediated lysis and polymerase chain reaction in the verification of therapeutic efficacy in Chagas disease]. Rev Soc Bras Med Trop (2006) 0.75
Case 2-2010: a man with abdominal and flank pain. N Engl J Med (2010) 0.75
Neonatal listeriosis: the importance of placenta histological examination-a case report. AJP Rep (2011) 0.75
The art of risk stratification in Chagas' disease. J Cardiovasc Electrophysiol (2008) 0.75
Analytical performance vs clinical use of natriuretic peptide measurements. Arch Intern Med (2010) 0.75
Predicting prognosis in patients with Chagas disease: why are the results of various studies so different? Int J Cardiol (2009) 0.75
Is reclassification of intermediate-risk subjects by coronary artery calcium scoring clinically useful? J Am Coll Cardiol (2011) 0.75
There is high incidence of skin cells in the first and third drops of cerebrospinal fluid in spinal anesthesia. Braz J Anesthesiol (2013) 0.75
[The impact of the extensive chemical control of Triatoma infestans on the incidence of acute cases and the prevalence of human Chagas disease. The example of Montalvânia, Minas Gerais State]. Rev Soc Bras Med Trop (2004) 0.75
[Cardiovascular magnetic resonance and computed tomography imaging guidelines of the Brazilian Society of Cardiology]. Arq Bras Cardiol (2006) 0.75
There is high incidence of skin cells in the first and third drops of cerebrospinal fluid in spinal anesthesia. Braz J Anesthesiol (2014) 0.75
Economic analysis of drug-eluting coronary stents in Brazil: a choice for all or just for a few patients? Arq Bras Cardiol (2007) 0.75